Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis.

Affiliation

Department of Clinical Neurosciences, University of Calgary, Canada; Department of Community Health Sciences, University of Calgary, Canada. Electronic address: [Email]

Abstract

Increasing systemic prolactin levels improves remyelination and neuronal survival in animal models of Multiple Sclerosis (MS), but it has been suggested that this therapeutic strategy may also increase inflammatory responses, and potentially harm patients. We analyzed serum prolactin and cytokine, chemokine and growth factor levels in sera from MS patients enrolled in two clinical trials who were treated with domperidone, a generic drug that increases systemic prolactin levels. In patients treated with domperidone, molecule levels changed little during follow up, while prolactin levels increased several-fold. We found no significant association between prolactin levels and radiological or clinical outcome.

Keywords

CNS,Multiple sclerosis,Neuroinflammation,Prolactin,

OUR Recent Articles